Silo pharma announces completion of fda pre-ind meeting to advance development of spc-15 for treatment of ptsd

Proposal submitted for fda 505(b)(2) regulatory pathway for spc-15 approval advancing path to ind submission for first-in-human trials sarasota, fl, sept. 10, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the completion of a pre-investigational new drug (pre-ind) meeting with the u.s. food and drug administration (fda) regarding the company's development plan for spc-15, an intranasal prophylactic treatment for post-traumatic stress disorder (ptsd) and stress-induced anxiety disorder.
SILO Ratings Summary
SILO Quant Ranking